Asosiy kontentga oʻtish
AkademScholar

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBasetez oradaDasturchilar API
Mualliflar

Nargiza Parpieva

Soʻnggi maʼlum muassasa:
Tashkent Pediatric Medical Institute
ORCID:
0000-0002-0360-1333
3
h-indeks
0
i10-indeksi
37
Iqtiboslar
49
Asarlar
Vaqt boʻyicha

Vaqt boʻyicha tahlil

Iqtibos sharhi

Yillar boʻyicha nashrlar (ustun) va iqtiboslar (chiziq)

  • Nashrlar
  • Iqtiboslar
051015200510152020172018201920202021202220232024202520262017: Nashrlar 1, Iqtiboslar 12018: Nashrlar 2, Iqtiboslar 02019: Nashrlar 4, Iqtiboslar 02020: Nashrlar 4, Iqtiboslar 62021: Nashrlar 18, Iqtiboslar 162022: Nashrlar 2, Iqtiboslar 22023: Nashrlar 1, Iqtiboslar 22024: Nashrlar 7, Iqtiboslar 82025: Nashrlar 3, Iqtiboslar 12026: Nashrlar 0, Iqtiboslar 1

Iqtibos tarixi

0510152020172018201920202021202220232024202520262017: Iqtiboslar 12018: Iqtiboslar 02019: Iqtiboslar 02020: Iqtiboslar 62021: Iqtiboslar 162022: Iqtiboslar 22023: Iqtiboslar 22024: Iqtiboslar 82025: Iqtiboslar 12026: Iqtiboslar 1

Nashr tarixi

0510152020172018201920202021202220232024202520262017: Nashrlar 12018: Nashrlar 22019: Nashrlar 42020: Nashrlar 42021: Nashrlar 182022: Nashrlar 22023: Nashrlar 12024: Nashrlar 72025: Nashrlar 32026: Nashrlar 0

h-indeks evolyutsiyasi

Yillar boʻyicha jamlangan h-indeks

0134520172018201920202021202220232024202520262017: h-indeks 12018: h-indeks 12019: h-indeks 12020: h-indeks 22021: h-indeks 32022: h-indeks 32023: h-indeks 32024: h-indeks 32025: h-indeks 32026: h-indeks 3

Eng koʻp iqtibos qilingan asarlar

  1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis20225 iqtibos
  2. Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study20154 iqtibos
  3. Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan20164 iqtibos
  4. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan20163 iqtibos
  5. Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan20203 iqtibos
  6. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan20223 iqtibos
  7. ‘They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan20162 iqtibos
  8. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–201820212 iqtibos
  9. Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?20212 iqtibos
  10. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan20181 iqtibos
AkademIndex'da koʻrish →